MeiraGTx's AAV-GAD gene therapy for Parkinson's disease met primary endpoint in a Phase I/II trial. High-dose group showed significant improvement in MDS-UPDRS score. The therapy aims to deliver GAD enzyme to reduce motor symptoms with a one-time infusion.